Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

A doctor has issued an warning as to why Ozempic shouldn't be used for weight loss as it does one alarming thing to body.

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Bio-Techne surpasses profit expectations with significant growth in its research products, leading to the announcement of a ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Just today, this drug became more widely available. Some product is now facing a recall following an apparent storage error.